Additionally, the 36-month beta value for EDIT is 2.11. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 9 rating it as “hold,” and 0 rating it as “sell.”
The public float for EDIT is 82.23M and currently, short sellers hold a 15.99% ratio of that float. The average trading volume of EDIT on March 26, 2025 was 3.96M shares.
EDIT) stock’s latest price update
Editas Medicine Inc (NASDAQ: EDIT)’s stock price has gone decline by -2.66 in comparison to its previous close of 1.30, however, the company has experienced a -8.96% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-20 that Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J.
EDIT’s Market Performance
Editas Medicine Inc (EDIT) has seen a -8.96% fall in stock performance for the week, with a -31.97% decline in the past month and a -3.40% plunge in the past quarter. The volatility ratio for the week is 6.77%, and the volatility levels for the past 30 days are at 11.50% for EDIT. The simple moving average for the last 20 days is -18.23% for EDIT’s stock, with a simple moving average of -58.06% for the last 200 days.
Analysts’ Opinion of EDIT
Stifel gave a rating of “Hold” to EDIT, setting the target price at $3 in the report published on December 13th of the previous year.
EDIT Trading at -15.92% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.32% of loss for the given period.
Volatility was left at 11.50%, however, over the last 30 days, the volatility rate increased by 6.77%, as shares sank -31.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.05% upper at present.
During the last 5 trading sessions, EDIT fell by -8.99%, which changed the moving average for the period of 200-days by -76.70% in comparison to the 20-day moving average, which settled at $1.5475. In addition, Editas Medicine Inc saw -0.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Lucera Erick, who sale 4,109 shares at the price of $1.71 back on Mar 04 ’25. After this action, Lucera Erick now owns 112,720 shares of Editas Medicine Inc, valued at $7,030 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 16,632 shares at $1.71 during a trade that took place back on Mar 04 ’25, which means that O’Neill Gilmore Neil is holding 295,474 shares at $28,452 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -7.77 for the present operating margin
- 0.86 for the gross margin
The net margin for Editas Medicine Inc stands at -7.34. The total capital return value is set at -0.95. Equity return is now at value -98.10, with -56.40 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -6.0.
Currently, EBITDA for the company is -233.11 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.29. The receivables turnover for the company is 1.99for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In conclusion, Editas Medicine Inc (EDIT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
